Insulet (PODD) Stock Overview
Develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 4/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PODD Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Insulet Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$318.59 |
| 52 Week High | US$353.50 |
| 52 Week Low | US$226.50 |
| Beta | 1.4 |
| 1 Month Change | -4.47% |
| 3 Month Change | 12.09% |
| 1 Year Change | 34.66% |
| 3 Year Change | 40.35% |
| 5 Year Change | 27.75% |
| Change since IPO | 1,896.18% |
Recent News & Updates
Recent updates
Market Participants Recognise Insulet Corporation's (NASDAQ:PODD) Revenues Pushing Shares 26% Higher
Sep 06
There May Be Reason For Hope In Insulet's (NASDAQ:PODD) Disappointing Earnings
Aug 14Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold
Aug 14Insulet (NASDAQ:PODD) Has A Rock Solid Balance Sheet
Aug 04Does Insulet (NASDAQ:PODD) Deserve A Spot On Your Watchlist?
Jul 22Insulet (NASDAQ:PODD) Shareholders Will Want The ROCE Trajectory To Continue
Jun 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
May 28Subdued Growth No Barrier To Insulet Corporation (NASDAQ:PODD) With Shares Advancing 26%
May 15We Ran A Stock Scan For Earnings Growth And Insulet (NASDAQ:PODD) Passed With Ease
Apr 21Does Insulet (NASDAQ:PODD) Have A Healthy Balance Sheet?
Apr 07Insulet Leans Bullish (Technical Analysis)
Mar 18Calculating The Intrinsic Value Of Insulet Corporation (NASDAQ:PODD)
Mar 05Insulet (NASDAQ:PODD) Is Experiencing Growth In Returns On Capital
Feb 18Earnings Not Telling The Story For Insulet Corporation (NASDAQ:PODD)
Jan 25What Is Insulet Corporation's (NASDAQ:PODD) Share Price Doing?
Jan 13Here's Why Insulet (NASDAQ:PODD) Can Manage Its Debt Responsibly
Dec 18Here's Why Insulet (NASDAQ:PODD) Has Caught The Eye Of Investors
Dec 04Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Nov 20Does This Valuation Of Insulet Corporation (NASDAQ:PODD) Imply Investors Are Overpaying?
Nov 20Returns At Insulet (NASDAQ:PODD) Are On The Way Up
Nov 08Insulet: Turning More Constructive, Valuations Still Stretched
Sep 05
Omnipod 5'S Global Expansion And New Integrations Promise Growth Amid Market And Manufacturing Risks
Expansion into new international markets and integration with leading diabetes sensors position Insulet for increased global penetration and competitive advantage.Insulet Corporation: Insulin Pump Provider Fighting Back After Torrid 2023
Jun 11Insulet: Insulating Patients, Investors Still Have To Wait
Mar 28Shareholder Returns
| PODD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.3% | 1.6% | 1.7% |
| 1Y | 34.7% | -3.1% | 14.5% |
Return vs Industry: PODD exceeded the US Medical Equipment industry which returned -3.1% over the past year.
Return vs Market: PODD exceeded the US Market which returned 14.5% over the past year.
Price Volatility
| PODD volatility | |
|---|---|
| PODD Average Weekly Movement | 4.3% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PODD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PODD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 3,900 | Ashley McEvoy | www.insulet.com |
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
Insulet Corporation Fundamentals Summary
| PODD fundamental statistics | |
|---|---|
| Market cap | US$22.43b |
| Earnings (TTM) | US$236.10m |
| Revenue (TTM) | US$2.36b |
Is PODD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PODD income statement (TTM) | |
|---|---|
| Revenue | US$2.36b |
| Cost of Revenue | US$703.70m |
| Gross Profit | US$1.66b |
| Other Expenses | US$1.42b |
| Earnings | US$236.10m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Nov 06, 2025
| Earnings per share (EPS) | 3.35 |
| Gross Margin | 70.18% |
| Net Profit Margin | 10.01% |
| Debt/Equity Ratio | 95.7% |
How did PODD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/18 01:26 |
| End of Day Share Price | 2025/10/17 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insulet Corporation is covered by 49 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| null null | Baird |
| Travis Steed | Barclays |